(Q36626046)

English

Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study

scientific article published on August 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study (English)

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

1 reference

based on heuristic

inferred from title

0 references

10

object named as

P J Selby

0 references

author name string

G D Hall

1

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

J M Brown

2

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

R E Coleman

3

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

M Stead

4

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

K S Metcalf

5

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

K R Peel

6

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

C Poole

7

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

M Crawford

8

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

B Hancock

9

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

T J Perren

11

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

language of work or name

0 references

publication date

1 August 2004

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

full work available at URL

http://eprints.whiterose.ac.uk/100572/

content deliverer

White Rose Research Online

object has role

published version

copyright license

Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported

0 references

https://doi.org/10.1038/sj.bjc.6602037

copyright license

Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported

object has role

published version

0 references

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

91

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

4

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

621-626

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

High-dose chemotherapeutic approaches to ovarian cancer management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364769

30 September 2017

Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364769

30 September 2017

Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364769

30 September 2017

Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patients. G.O.N.O. Gruppo Oncologic Nord Ovest

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364769

30 September 2017

Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364769

30 September 2017

Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364769

30 September 2017

Ovarian carcinoma: the role of chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364769

30 September 2017

A phase II study on escalating interferon doses in advanced ovarian carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364769

30 September 2017

Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364769

30 September 2017

Sensitivity of human ovarian carcinoma cells to interferon and other antitumor agents as assessed by an in vitro semi-solid agar technique.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364769

28 June 2018

Intraperitoneal recombinant alpha-2-interferon alternating with cisplatin as salvage therapy for minimal residual-disease ovarian cancer: a phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364769

28 June 2018

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364769

20 September 2018

Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum-sensitive ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15305182

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Leukocyte interferon (IFN alpha) in patients with epithelial ovarian carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15305182

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/15305182

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intermittent cisplatin therapy for stage-III ovarian cancer patients following clinical remission

1 reference

https://pubmed.ncbi.nlm.nih.gov/15305182

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6602037

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

10.1038/SJ.BJC.6602037

0 references

0 references

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

ResearchGate publication ID

0 references

2-s2.0-4344703324

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36626046&oldid=2199113591"